Enobia Pharma Announces Positive Interim Clinical Results With ENB-0040

MONTREAL, June 11, 2009 (GLOBE NEWSWIRE) -- Enobia Pharma, an emerging biotech company focused on developing novel therapeutics for serious bone disorders, announced that results from two early-stage studies of the company's lead product, ENB-0040, were presented today during a Symposium Session at the Endocrine Society's 91st Annual Meeting (ENDO 09) in Washington, DC. ENB-0040, a bone targeted enzyme replacement therapy, is under investigation as a treatment for hypophosphatasia (HPP), a severe, sometimes deadly genetic bone disorder.